3 Drugs to Market in 2010 (Market Cap 9,6 Mio$ ) !!!!!!

[BiotechMaster]

PMBS.OB is a real unknown gem .....This stock has tremendous upside Potential !!!!

Please take a few minutes and read the following

GLTA


Puramed (PMBS.OB)

Market Cap: 9,6 Mio$
Price: 0,76 $

Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million

Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar

PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.

Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).

PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.

The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.

With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.

About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

---------------------
Pipeline


LipiGesic™ M

LipiGesic™ M provides acute relief from migraine headaches, and contains the herbs feverfew and ginger as principal ingredients. PuraMed believes that its specific formulation of these herbs for its migraine remedy is unique and proprietary, providing relief from these severe headaches in minutes. The Company believes it will capture a material segment of the huge migraine headache remedy market. We believe that Americans spend in excess of $6 billion annually on headache pain relievers, and that over half of sufferers of migraine headaches rely exclusively on non-prescription medications.

We believe that at least 30 million Americans suffer from chronic migraine headaches with over 20 million of them having “severe” migraine conditions. Thus migraine headaches constitute a severe and disabling condition for millions of people. We further believe that the economic burden alone to the U.S. economy is in excess of $20 billion annually.

LipiGesic™ M is effective, available as a non-prescription remedy, without any known side effects, and affordable compared to more expensive migraine drugs based on prescription chemical formulations.

LipiGesic™ PM

LipiGesic™ PM is a new class of non-prescription sleep aid without any known side effects, and contains a proprietary blend of natural ingredients including Valerian, St. John’s Wort, and Chamomile. We believe that the proprietary blend of these ingredients provides an effective remedy for insomnia and other sleep disorders. The sleep aid market features products based primarily on chemical antihistamines.

Accordingly, the LipiGesic™ PM product provides a wide open market opportunity for an effective, natural alternative to prescription medications, which are somewhat addictive and often cause withdrawal symptoms and other side effects. We have priced LipiGesic™ PM as a premium sleep aid product, which provides us with a projected gross margin of approximately 80%. This large margin should leave us substantial room for ample introductory promotion, product allowances and other incentives conducive to achieving rapid market penetration.

Similar to the migraine remedy market, the market for sleep aid products represents a very large segment of the overall healthcare products marketplace. We believe that over half of all adults in the U.S. suffer from sleep disorders, and that many of them experience persistent insomnia. The National Center on Sleep Disorders has reported that there are as many as 70 million problem sleepers in the U.S. with many of them suffering from chronic sleep disorders. We believe that insomnia is second only to pain as a healthcare complaint.

Future LipiGesic™ Products

We have completed development of additional non-prescription products, which we intend to launch commercially over the next couple years after establishing a solid market for our initial two products. These other PuraMed products include:

LipiGesic™ H – provides relief for common tension headaches which afflict a majority of American adults from time to time. This remedy provides headache relief features a unique proprietary formulation of St. John’s Wort and common aspirin.

LipiGesic™ Smoker’s Pal – provides relief from the symptoms associated with nicotine withdrawal with the added benefit of an appetite suppressant.

LipiGesic™ RLS – provides relief of problematic leg cramps associated with Restless Leg Syndrome affecting a large segment of the population in the U.S.

LipiGesic™ GI – provides relief of symptoms associated with nighttime reflux disorders.

LipiGesic™ CS – provides fast relief for canker sore outbreaks.

[BiotechMaster]

Please do your own DD ........

FAQ
PuraMed BioScience

Promo Video
PuraMed BioScience

Presentation
http://www.puramedbioscience.com/Pur...%201-13-10.ppt


PuraMed BioScience Begins to Generate Revenue From Launch of Direct Response Commercial Featuring LipiGesic(TM) M


Press Release Source: PuraMed BioScience On Monday January 4, 2010, 9:00 am EST

SCHOFIELD, Wis., Jan. 4, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS - News) announced today that it has begun to generate revenue for the first time as a result of its e-commerce website, www.MyMigraineGone.com, and direct response commercial featuring LipiGesic(TM) M, a non-prescription medication for migraine headaches.

"We are very pleased with how strong the initial results have been from our test launch of the direct response commercial," said PuraMed BioScience CEO Russell Mitchell. "We are now for the first time generating revenue and have truly begun to create awareness for our product and Company. We continue to accelerate our testing by identifying additional key markets and stations to further test our commercial," added Mitchell.

The commercial was first launched the week of Dec. 14 and will continue to air in select test markets before launching a major national direct response campaign.

The commercial is available for viewing on the corporate website at PuraMed BioScience. Click on the "Investor" tab, then the "Promotional Media" tab to view.